Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

被引：0
作者：
Rha, Sun Young
Lee, Jeeyun
Ryu, Min-Hee
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
Oh, Do-Youn
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Merck & Co Inc, Rahway, NJ USA
[5] MSD France, Puteaux La Defense, France
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428 / 428
页数：1
相关论文
共 50 条
[21]   Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study [J].
Chalabi, M. ;
Verschoor, Y. L. ;
Van De Haar, J. ;
van den Berg, J. ;
Kodach, L. ;
van Sandick, J. ;
van Dieren, J. ;
Balduzzi, S. ;
Grootscholten, M. C. ;
Veenhof, X. ;
Hartemink, K. ;
Vollebergh, M. ;
Owers, E. ;
Bartels-Rutten, A. ;
den Hartog-Lievaart, P. ;
van Leerdam, M. ;
Schumacher, T. N. ;
Haanen, J. B. A. G. ;
Voest, E. E. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1106-S1106
[22]   Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585 [J].
Shitara, Kohei ;
Bang, Yung-Jue ;
Wyrwicz, Lucjan S. ;
Rha, Sun Young ;
Oshima, Takashi ;
Di Bartolomeo, Maria ;
Park, Young-Kyu ;
Lonardi, Sara ;
Weber, Patricio Eduardo Yanez ;
Yen, Chia-Jui ;
Metges, Jean-Philippe ;
Garrido, Marcelo ;
Moehler, Markus H. ;
Pelles-Avraham, Sharon ;
Yong, Wei-Peng ;
Spallanzani, Andrea ;
Jensen, Erin ;
Krishnan, Radha ;
Shih, Chie-Schin ;
Al-Batran, Salah-Eddin .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23]   Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial. [J].
Rha, Sun Young ;
Revil, Cedric ;
Valderrama, Adriana ;
Wang, Liya ;
Andre, Manon ;
McCarthy, Grant ;
Young, Kate .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) :354-354
[24]   KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma (vol 17, pg 2847, 2021) [J].
Tabernero, J. .
FUTURE ONCOLOGY, 2023, 19 (17) :1229-1229
[25]   Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study [J].
Tabernero, J. ;
Van Cussem, E. ;
Bang, Y. ;
Fuchs, C. ;
Wyrwicz, L. ;
Lee, K. ;
Kudaba, I. ;
Garrido, M. ;
Chung, C. ;
Salguero, C. Castro ;
Mansoor, W. ;
Braghiroli, M. ;
Goekkurt, E. ;
Chao, J. ;
Wainberg, Z. ;
Kher, U. ;
Shah, S. ;
Karg, S. ;
Shitara, K. .
ANNALS OF ONCOLOGY, 2019, 30 :152-+
[26]   Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan [J].
Morimoto, Kosuke ;
Moriwaki, Kensuke ;
Shimozuma, Kojiro ;
Nakayama, Takeo .
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) :1188-1197
[27]   Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan [J].
Kosuke Morimoto ;
Kensuke Moriwaki ;
Kojiro Shimozuma ;
Takeo Nakayama .
Journal of Gastroenterology, 2023, 58 :1188-1197
[28]   Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study [J].
Chung, H. C. ;
Bang, Y-J. ;
Tabernero, J. ;
Van Cutsem, E. ;
Fuchs, C. S. ;
Wyrwicz, L. ;
Lee, K-W. ;
Kudaba, I. ;
Garrido, M. ;
Castro, H. ;
Mansoor, W. ;
Braghiroli, M. I. ;
Goekkurt, E. ;
Chao, J. ;
Wainberg, Z. A. ;
Kher, U. ;
Shah, S. ;
Shitara, K. .
ANNALS OF ONCOLOGY, 2019, 30
[29]   KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma [J].
Tabernero, J. ;
Bang, Y. ;
Van Cutsem, E. ;
Fuchs, C. ;
Janjigian, Y. ;
Bhagia, P. ;
Li, K. ;
Adelberg, D. ;
Qin, S. .
ANNALS OF ONCOLOGY, 2020, 31 :S101-S102
[30]   Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma [J].
Zhou, Zhifeng ;
Yang, Yanqing ;
Chen, Shaofang ;
You, Maojin .
FRONTIERS IN IMMUNOLOGY, 2025, 16
12345